| __timestamp | Johnson & Johnson | MorphoSys AG |
|---|---|---|
| Wednesday, January 1, 2014 | 22746000000 | 77000 |
| Thursday, January 1, 2015 | 21536000000 | 77000 |
| Friday, January 1, 2016 | 21685000000 | 97000 |
| Sunday, January 1, 2017 | 25354000000 | 33000 |
| Monday, January 1, 2018 | 27091000000 | 1796629 |
| Tuesday, January 1, 2019 | 27556000000 | 12085198 |
| Wednesday, January 1, 2020 | 28427000000 | 9174146 |
| Friday, January 1, 2021 | 23402000000 | 32200000 |
| Saturday, January 1, 2022 | 24596000000 | 48620000 |
| Sunday, January 1, 2023 | 26553000000 | 58355000 |
| Monday, January 1, 2024 | 27471000000 |
Infusing magic into the data realm
In the world of pharmaceuticals, Johnson & Johnson and MorphoSys AG present a fascinating contrast in their cost of revenue trends over the past decade. From 2014 to 2023, Johnson & Johnson's cost of revenue has shown a steady increase, peaking in 2020 with a 25% rise from its 2014 figures. This growth reflects the company's robust expansion and investment in production capabilities.
On the other hand, MorphoSys AG, a smaller player in the industry, has experienced a more volatile journey. Starting with minimal costs in 2014, the company saw a dramatic surge by 2023, with costs increasing by over 75,000%. This sharp rise indicates MorphoSys AG's aggressive scaling and market penetration efforts.
These trends highlight the diverse strategies employed by pharmaceutical giants and emerging companies in navigating the competitive landscape.
Cost of Revenue Comparison: Johnson & Johnson vs Regeneron Pharmaceuticals, Inc.
Johnson & Johnson vs Viatris Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Johnson & Johnson and Cytokinetics, Incorporated's Expenses
Johnson & Johnson vs Agios Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Bristol-Myers Squibb Company and MorphoSys AG
Comparing Cost of Revenue Efficiency: Vertex Pharmaceuticals Incorporated vs MorphoSys AG
Analyzing Cost of Revenue: United Therapeutics Corporation and MorphoSys AG
Cost Insights: Breaking Down Incyte Corporation and MorphoSys AG's Expenses
Cost of Revenue Trends: MorphoSys AG vs Vericel Corporation
Analyzing Cost of Revenue: MorphoSys AG and Travere Therapeutics, Inc.
Cost of Revenue: Key Insights for MorphoSys AG and BioCryst Pharmaceuticals, Inc.
Cost of Revenue Trends: MorphoSys AG vs Evotec SE